Ironwood Investment Management LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,074 shares of the company’s stock after acquiring an additional 20 shares during the quarter. Ironwood Investment Management LLC’s holdings in Johnson & Johnson were worth $671,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Lenox Wealth Advisors Inc. boosted its stake in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares in the last quarter. Lbmc Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 0.4% during the first quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock valued at $461,000 after purchasing an additional 14 shares in the last quarter. Stratford Consulting LLC boosted its stake in shares of Johnson & Johnson by 0.6% during the second quarter. Stratford Consulting LLC now owns 2,728 shares of the company’s stock valued at $361,000 after purchasing an additional 16 shares in the last quarter. North Point Portfolio Managers Corp OH boosted its stake in shares of Johnson & Johnson by 0.7% during the second quarter. North Point Portfolio Managers Corp OH now owns 2,923 shares of the company’s stock valued at $387,000 after purchasing an additional 20 shares in the last quarter. Finally, Cascade Investment Advisors Inc. boosted its stake in shares of Johnson & Johnson by 0.3% during the second quarter. Cascade Investment Advisors Inc. now owns 7,048 shares of the company’s stock valued at $932,000 after purchasing an additional 23 shares in the last quarter. 66.06% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson (NYSE:JNJ) opened at $140.08 on Friday. The company has a current ratio of 1.34, a quick ratio of 1.01 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a fifty-two week low of $109.32 and a fifty-two week high of $144.35. The stock has a market cap of $376,327.72, a price-to-earnings ratio of 19.62, a P/E/G ratio of 2.85 and a beta of 0.82.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.68%. The firm had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter last year, the company posted $1.68 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

Several brokerages have weighed in on JNJ. UBS AG restated a “buy” rating and issued a $148.00 target price (up from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and raised their target price for the company from $125.00 to $130.00 in a research note on Wednesday, September 20th. BMO Capital Markets restated a “buy” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research note on Friday, September 1st. Alembic Global Advisors downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Finally, Wells Fargo & Company upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and raised their target price for the company from $140.00 to $149.00 in a research note on Monday, October 9th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $143.70.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/ironwood-investment-management-llc-raises-stake-in-johnson-johnson-jnj/1679520.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.